Sections
You are here: Home BHF Centre of Research Excellence Researchers Colin Baigent

Colin Baigent FFPH FRCP

Professor of Epidemiology and Honorary Consultant in Public Health
Clinical trials and epidemiology

Divisional Research Themes

  • Clinical Epidemiology
  • Cardiovascular Science

Cardiovascular subthemes

Collaborators

Selected Publications

Web Personal Website
Email
Tel 01865 743866
Contact address Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LF, United Kingdom
Department Nuffield Department of Clinical Medicine
College Green Templeton College
Colin Baigent

Prof Colin Baigent

Colin Baigent’s main research interest is the use of large-scale evidence, typically involving randomized trials and meta-analyses of those trials, for the prevention and treatment of cardiovascular disease. He coordinates two separate areas of research:

(1) Large-scale collaborative meta-analyses of randomised trials: These very large projects generally involve detailed individual participant data from each trial, and the resulting analyses can provide reliable assessments of the benefits and risks of drug regimens for particular types of patients. They include the well-known Antithrombotic Trialists’ (ATT) and Cholesterol Treatment Trialists’ (CTT) Collaborations, which have helped establish the appropriate use of aspirin and statins in a wide range of people and conditions. More recently a new collaborative meta-analysis of trials has been established in order to assess the cardiovascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs and COX-2 inhibitors.

(2) Randomized trials of cardiovascular drugs in chronic kidney disease: Epidemiological associations between cardiovascular disease risk factors (eg, LDL cholesterol and blood pressure) and vascular disease outcomes are seriously distorted by “reverse causality” in advanced renal disease, producing associations that are the reverse of what might be expected. When treatments exist that can modify such risk factors, randomized trials of such treatments are an effective method for avoiding reverse causality and establishing the true relevance of those exposures to vascular disease. Colin has established an international collaboration of nephrologists which is conducting the Study of Heart and Renal Protection (SHARP), a randomized trial assessing the effects of cholesterol-lowering therapy in patients with chronic kidney disease. The trial involves 9,438 patients in 380 hospitals in 18 countries, and is scheduled for completion in 2010.